Hearing Therapy Pioneer Auris Medical Gets $50 Million Series C Financing
This article was originally published in The Pink Sheet Daily
Auris Medical AG has completed Europe’s largest biotech investing round so far this year, led by Sofinnova Partners and Sofinnova Ventures, and hopes to advance the development of new otologic drugs for hearing dysfunction.
You may also be interested in...
The Paris-based start-up has raised €32 million from venture investors to address two orphan eye disorders, taking advantage of new research and manufacturing techniques in gene therapy.
Plus news on recent financings by Elcelyx, Jounce Therapeutics, Retrophin and e-Therapeutics.
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.